Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 28322690)

Published in Emerg Infect Dis on April 01, 2017

Authors

Scott B Halstead

Articles cited by this

Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med (2009) 17.89

Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg (1952) 13.73

Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet (2016) 10.08

Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res (2003) 4.90

Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg (1988) 4.65

Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. Cell Stem Cell (2016) 4.54

Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med (1970) 4.30

Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis (2004) 3.81

Isolation of Zika virus from Aedes aegypti mosquitoes in Malaysia. Am J Trop Med Hyg (1969) 3.78

Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise. Cell (2016) 3.42

Zika Virus. Clin Microbiol Rev (2016) 3.34

Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe (2010) 3.33

Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16

Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol (2006) 3.07

Zika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo State. J Hyg (Lond) (1979) 2.77

Neutralizing antibodies against certain viruses in the sera of residents of India. J Immunol (1954) 2.45

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol (2013) 2.29

Infection of monocytes during measles. J Infect Dis (1993) 2.14

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol (2016) 2.08

Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg (2007) 2.06

Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis (2002) 2.03

Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia. N Engl J Med (2016) 1.91

Neutralizing antibodies against arthropod-borne viruses in the sera of long-time residents of Malaya and Borneo. Am J Hyg (1954) 1.90

Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis (2007) 1.88

Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg (2009) 1.87

Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica (2002) 1.75

Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J Infect Dis (2007) 1.71

Detection of Zika Virus in Semen. Emerg Infect Dis (2016) 1.69

Acute measles in patients with and without neurological involvement: distribution of measles virus antigen and RNA. J Infect Dis (1988) 1.59

Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology (2008) 1.54

Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature (2016) 1.52

A Susceptible Mouse Model for Zika Virus Infection. PLoS Negl Trop Dis (2016) 1.47

Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. J Infect Dis (1973) 1.42

A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis (2013) 1.33

Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A (2016) 1.31

Serological survey for a arthropod-borne virus infections in the Philippines. Am J Trop Med Hyg (1958) 1.23

Guillain-Barré syndrome associated with Zika virus infection. Lancet (2016) 1.22

Zika Virus and the Guillain-Barré Syndrome - Case Series from Seven Countries. N Engl J Med (2016) 1.18

Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections. Front Immunol (2014) 1.13

Cross-infection enhancement among African flaviviruses by immune mouse ascitic fluids. Cytobios (1987) 1.09

Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Hum Pathol (2014) 1.06

Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol (2012) 1.05

Dengue Hemorrhagic Fever at 60 Years: Early Evolution of Concepts of Causation and Treatment. Microbiol Mol Biol Rev (2015) 0.96

How Did Zika Virus Emerge in the Pacific Islands and Latin America? MBio (2016) 0.90

Dengue virus antibodies enhance Zika virus infection. Clin Transl Immunology (2016) 0.86

Guillain-Barré Syndrome After Zika Virus Infection in Brazil. Am J Trop Med Hyg (2016) 0.85

The Epidemic of Zika Virus-Related Microcephaly in Brazil: Detection, Control, Etiology, and Future Scenarios. Am J Public Health (2016) 0.83

The Zika Pandemic - A Perfect Storm? PLoS Negl Trop Dis (2016) 0.80

Maternal Antibody-Mediated Disease Enhancement in Type I Interferon-Deficient Mice Leads to Lethal Disease Associated with Liver Damage. PLoS Negl Trop Dis (2016) 0.77

Articles by these authors

Dengue: a continuing global threat. Nat Rev Microbiol (2010) 9.96

Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis (2002) 3.77

Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg (2009) 3.42

Evaluation of diagnostic tests: dengue. Nat Rev Microbiol (2010) 2.91

Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet (2002) 2.56

Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS Negl Trop Dis (2010) 2.45

Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis (2004) 2.43

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol (2013) 2.29

Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis (2009) 2.26

Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet (2005) 1.84

Cost-effectiveness of a pediatric dengue vaccine. Vaccine (2004) 1.83

Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica (2002) 1.75

Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies. J Infect Dis (2007) 1.74

Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com. Vaccine (2007) 1.63

Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am J Trop Med Hyg (2006) 1.45

Reappearance of chikungunya, formerly called dengue, in the Americas. Emerg Infect Dis (2015) 1.37

Association between sex, nutritional status, severity of dengue hemorrhagic fever, and immune status in infants with dengue hemorrhagic fever. Am J Trop Med Hyg (2005) 1.34

Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis (2007) 1.33

Controlling dengue with vaccines in Thailand. PLoS Negl Trop Dis (2012) 1.25

How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol (2010) 1.23

The wages of original antigenic sin. Emerg Infect Dis (2010) 1.21

Volume replacement in infants with dengue hemorrhagic fever/dengue shock syndrome. Am J Trop Med Hyg (2006) 1.13

Call to action for dengue vaccine failure. Emerg Infect Dis (2013) 1.00

Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiol Spectr (2014) 0.97

Dengue vascular permeability syndrome: what, no T cells? Clin Infect Dis (2012) 0.96

Recombination and flavivirus vaccines: a commentary. Vaccine (2005) 0.94

Dengue 1 virus and dengue hemorrhagic fever, French Polynesia, 2001. Emerg Infect Dis (2009) 0.90

Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001-2002. Int J Infect Dis (2012) 0.87

Assessing the prognosis of dengue-infected patients. F1000 Med Rep (2009) 0.83

Vaccines aplenty. Curr Opin Infect Dis (2002) 0.79

Virus role during intraepidemic increase in dengue disease severity. Vector Borne Zoonotic Dis (2011) 0.79

Measuring dengue enhancing antibodies: caveats. J Infect Dis (2006) 0.76

Interview with Scott B. Halstead, M.D. Vector Borne Zoonotic Dis (2007) 0.75